Related Experiment Video
Updated: Jul 19, 2026
07:30
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Are sulfonylureas passé?
Jennifer B Green1, Mark N Feinglos
1Duke University Medical Center, Division of Endocrinology, DUMC Box 3222, Baker House, Room 280, Durham, NC 27710, USA. green094@mc.duke.edu
Current Diabetes Reports
|November 2, 2006
Summary
Sulfonylureas manage type 2 diabetes but offer limited long-term glycemic control and risks like hypoglycemia. Newer agents, such as glimepiride, show promise for improved cardiac safety in diabetes treatment.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Sulfonylureas and rapid insulin secretagogues are established treatments for type 2 diabetes.
- Their mechanism of action is understood, and they are generally well-tolerated.
- However, long-term glycemic control can be challenging, with risks of hypoglycemia and weight gain.
Purpose of the Study:
- To review the efficacy and safety of sulfonylurea therapy for type 2 diabetes.
- To discuss concerns regarding cardiac outcomes and ischemic preconditioning.
- To highlight newer agents like glimepiride for improved myocardial safety.
Main Methods:
- Literature review of sulfonylureas and related insulin secretagogues.
- Analysis of clinical data on glycemic control, side effects, and cardiac outcomes.
- Comparison of traditional sulfonylureas with newer agents like glimepiride.
Main Results:
- Sulfonylureas provide short-term glycemic management but often fail long-term.
- Hypoglycemia and weight gain are significant potential side effects.
- Some sulfonylureas may negatively impact cardiac outcomes, while glimepiride shows better cardiac tolerability.
Conclusions:
- Sulfonylureas can be part of combination therapy for type 2 diabetes.
- Glimepiride represents a potentially safer option regarding cardiac effects.
- Careful patient selection and monitoring are crucial for sulfonylurea use.
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...